Session 5 - Alive and Thriving: Treatment, Care and Support for Adolescents Living with HIV

Caroline Foster, Imperial College Healthcare NHS Trust, United Kingdom








Perinatal HIV: your 20s and beyond



Objectives

- To describe treatment approaches to support young adults living with perinatal HIV to achieve viral suppression.
- To describe the key considerations for fertility/managing pregnancy in young women with perinatal HIV.
- To understand mental health issues faced by adolescents and young adults living with HIV



Note: Data are for all children and young people alive who ever presented to medical services in the UK/Ireland, including children who have since transferred to adult care; those who subsequently died or were lost to follow-up are excluded from the year of death or loss to follow-up. All paediatric patients included, from date of first presentation to medical services in the UK, regardless of mode of acquisition (91% perinatal). CHIPS includes all diagnosed HIV-infected children known to be living in the UK/Ireland, of whom 58% were born abroad. Data for 2019 are incomplete as subject to reporting delay. Republic of Ireland ceased reporting in 2018; those reported up to that date are included here.

Mortality and HIV


- 15-19 years: Only age group were HIV mortality continues to rise¹
- Outcomes poorer at all stages of the care cascade (diagnosis, retention, access to treatment, viral suppression)² in all settings

¹Slogrove JIAS 2017, ²Enane Curr Op HIV AIDS 2018



Poor adherence is an adolescent norm

Foster, Ayers, Fidler. Ther Adv Inf Dis 2020




RISK BEHAVIOURS IN YOUTH WITH CHRONIC CONDITIONS


- current smoking
- illegal drugs
- early sexual debut
- eating disorder
- antisocial acts
- attempted suicide

- 1.32 (1.13, 1.54) 1.49 (1.15, 1.92)
- 1.33 (1.03, 1.72)
- 1.44 (1.26, 1.74)
- 1.48 (1.26, 1.74)
- 2.24 (1.55, 3.24)
- more likely to report 3 or > 4 simultaneous behaviours


JC Suris et al, 2007 J Begent CHIVA 2010


Prefrontal cortex maturation - 3rd decade impulse control, planning, emotional regulation





Less Developed







Afternoons, walk in, MDT, sexual health contraception vaccination, peer support, social care, finances, pregnancy and infant testing, "GP care"



Non-judgmental MDT Adherence Support Clinical Nurse specialist, Psychology, Peer counsellor, Dietician, Pharmacist, Social Services, Community Motivational Interviewing communication style Walk in access to Youth Friendly Service Transport costs supported

ART

Resistance, Simplification, Virtual Clinic Referral High genetic barrier regimen Pill size/number/formulation, Pill Glide SMS support, Hypnosis, Community DOT Financial Incentives, Food chain

Gastrostomy


LA-ART



POSITIVELY UK

Foster, Ayers, Fidler. Ther Adv Inf Dis 2020







13 per 1000

woman-years

pregnancy incidence rate among women with PHIV

Pregnancies in women with perinatal HIV (PHIV)

- Of 630 women reported to NSHPC in childhood, 45 (7%) had at least one pregnancy reported
- Pregnancy incidence rate lower in PHIV than in women of similar age in general UK population
- 70 pregnancies among 45 women with PHIV were compared with 184 pregnancies among 118 age-matched women with behaviourally-acquired HIV (BHIV)

65% 70 58% Percentage or median 60 BHIV PHIV 50 40% 39% 36% 40 30 21% 20.1 19.8 20% 19.1 20 13% 6% 5.6 10 3% 0 Born in UK/Ireland Age at diagnosis ART at conception Maternal baseline Age at first Termination of Detectable viral (years) conception (years) CD4+ count <200 load at delivery pregnancy (live births) cells/ul

Women with PHIV were 3x more likely to have detectable viral load near delivery [OR 3.22 (CI 1.22-8.48)]

For a link to full publication, visit www.ucl.ac.uk/nshpc/publications.



Maternal and pregnancy characteristics, PHIV vs. BHIV (data source: Byrne et al. 2017 AIDS)





Pregnancy prescribing: lessons learnt

- 24 year old
- PaHIV
- Prior poor adherence
- Suppressed on DTG/ABC/3TC
- Pregnant 5/40




CD4





Mid 2018: Switches to Ataz/r, TDF, FTC



VIRAL LOAD

04

Careful consideration when responding to new data: dolutegravir and pregnancy

C Foster1*, S Fidler12, EGH Lyall1 and GPT Taylor12

¹ Imperial College Healthcare NHS Trust, London, UK ² Imperial College, London, UK

Abstract

This case highlights the current complexities of managing women in the early stages of pregnancy presenting on dolutegravir-based regimens. When responding to new data, there is an important decision to be made, between the potential, uncertain risk of teratogenicity against the potential increased risk of *in utero* vertical transmission of HIV-1.

Keywords: dolutegravit, pregnancy, treatment switch

Introduction

A young adult taking Triumeq, a fixed dose combination of dolutegravir, lamivudine and abacavir attended HIV services with an unplanned 5-week (by dates) pregnancy. On that day, her CD4 cell count was 848 cells/mm³, CD4:8 ratio 0.5 and HIV viral load (VL) <20 copies/ml.

HV infection was first diagnosed at age 6 and she had a history of longstanding poor adherence to antiretroviral therapy (ART) presenting in 2016 with disseminated mycobacterium avium intracellulare with a nadir CD4 cell count of 5 cells/mm³. Despite antimicrobial therapy and excellent immune reconstitution on fully suppressive dolutegravir-based ART, recovery was complicated by bilateral hearing loss requiring augmentation.

Five days previously (18th May 2018) increased rates of neural tube defects (NTD) in infants conceived on dolutegravir were reported in the Botswana cohort: 4/426 infants. This was a rate of any NTD of 0.9% compared to an expected rate of 0.1% [1]. In response, the European Medicines Authority recommended 'If pregnancy is confirmed in the first trimester while a woman is taking dolutegravir, switch to an alternative treatment unless there is no suitable alternative' [2].

Outcome

Following discussions with the patient and her supporter, she switched to darunavir/ritonavir and abacavir co-formulated with lamivudine and additional folic acid. Concerns with adherence and previous resistance mutations impacted on non-nucleoside reverse transcriptase inhibitors favouring a boosted protease inhibitor regimen over raltegravir or efavirenz-based ART. At follow up, 21 days after the switch, she reported difficulties with adherence,

*Corresponding author: Caroline Foster, Imperial College Healthcare NHS Trust, London W2 1NY, UK Email: caroline.fosterS@nhs.net nausea and tiredness. Despite 16 months with suppressed viraemia on Triumeq, 21 days following ART switch her HIV VL was 1,505,162 copies RNA/ml and CD4 cell count had fallen to 242 cells/mm³, CD4:8 ratio 0.2. A week later she was switched back to Triumeq at 10 weeks' gestation. Her CD4 cell count was now 161 cells/mm³ and prophylaxis against *Pneumocystis jirovecii* pneumonia was re-instigated. She continues under fortnightly follow up until viral suppression is reqained.

Discussion

This case highlights the current complexities of managing women in the early stages of pregnancy presenting on dolutegravir-based regimens, particularly in those with a history of poor adherence in whom outcomes of treatment switches, that increase both pill burden and potential toxicity, are of concern. By 5 weeks' gestation, the fetal neural tube is already closed raising the question of benefit of switching after this time. When responding to new data, there is an important decision to be made, between the potential, uncertain risk of teratogenicity against the potential increased risk of *in utero* vertical transmission of HIV-1. The challenge now is to achieve viral re-suppression before delivery to prevent peripartum transmission, complex for a young woman who has struggled with adherence and now has the added aroiety that ART can harm her unborn child. In retrospect perhaps there was no 'suitable alternative'.

References


- World Health Organization. Statement on DTG. Potential safety issue affecting women Wing with HW using dolutogravir at the time of conception. 18 May 2018. Available at: www.who.int/medicines/publications/drugalerts/Statement_on_DTG_ 18 May_2018/ind.gdf (accessed June2018).
- European Medicines Agency. New study suggests risk of birth defects in bables born to women on HV medicine dolutogravit. Press release 18 May 2018. Available at: www.ema.europa.eu/ema/indox.jsp?curl-pages/news_and_events/news/ 2018/05/news_detail_002956.jsp8mid=WC0b01ac058004d5c1 (accessed June 2018).





Hindsight:

- Never tolerated a protease inhibitor based regimen in past
- Uninfected partner and infant at potential risk of infection if viral rebound
- Neural tube defects possible increased risk on dolutegravir but the neural tube closes by 26 days of pregnancy
 - Normal embryological development
 - Neural plate development -18th day
 - Cranial closure 24th day (upper spine)
 - Caudal closure 26th day (lower spine)





22 year old young woman living with PHIV requesting injectable ART

➤ CD4 70, VL 748,000

Long term poor adherence to ART

> 2015 CNS venous thrombosis (s/c LMWH)

Learning Disability

➢ Obesity


Novel Adherence Interventions in Perinatally Acquired HIV: PEG Insertion and Pill Glide. Zombori et al. Clin Drug Investig. 2020 Aug;40(8):765-772.



ART Treatment


Date	ART	CD4/VL	
8/97-10/97	NVP D4T DDI		
10/97-12/02	D4T DDI		
12/02-09/03	EFV ABC 3TC		
09/03-10/11	Off ART	CD4 fell to 195	
10/11-1/12	DRV/r TDF/FTC		
1/12-4/13	KAL liquid TDF/FTC	VL suppressed for 9/12	
4/13-2014	DRV/r TDF/FTC	Last VL <50 march 2013	Drug Resistance Interpretation: RT
2015-2018	DRV/r TDF/FTC	VL<50 then stopped	NRTI Resistance Mutations:NoneNNRTI Resistance Mutations:K103NOther Mutations:None
4/18-2/19	DTG + F/TAF	VL 24 then stopped	Non-Nucleoside RTI
			efavirenz (EFV)High-level resistanceetravirine (ETR)Susceptiblenevirapine (NVP)High-level resistancerilpivirine (RPV)Susceptible





Fertility evaluation in adults with perinatally acquired HIV-1 infection: a cross-sectional observational study *Pasvol et al AIDS in press 2020*





Mental Health

AALPHI Perinatal UK cohort: similar to matched HUE siblings, but higher than the general population Le Provost *AIDS Care* 2018

UK Risk factors for adverse Adolescent Mental Health

Expected rate of psychosis 1-2%

- Black ethnicity
- Migrant population
- Parental unemployment
- Looked after child

> Poverty

21% anxiety/depression4.5% suicide/self harm4% alcohol/drug dependency

7.5% psychotic episode median 21 yrs (r14-26) 66% suppressive ART Malik 2002 in press

Prescribing ART is the easy part

Late HIV/ART toxicity Neuropsychiatric 3rd generation Malignancy Renal Bone CVS Ols





Children adolescents, young adults and not so young adults of the 900 and Family Clinics

